Biodesix Inc

NASDAQ BDSX

Data sourced from

and

Download Data

Biodesix Inc Equity Multiplier 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024

Biodesix Inc Equity Multiplier 2 year CAGR is NA for the Trailing 12 Months (TTM) ending March 31, 2024. The Equity Multiplier measures the proportion of a company's assets that are financed by equity. It indicates the level of financial leverage in a company's capital structure. A higher ratio suggests a higher level of debt financing and indicates higher financial risk. The equity multiplier is useful in assessing the company's solvency and financial stability. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Biodesix Inc Equity Multiplier for the Trailing 12 Months (TTM) ending March 31, 2023 was 2.58, a -51.73% change year over year.
Biodesix Inc Equity Multiplier for the Trailing 12 Months (TTM) ending March 31, 2022 was 5.34, a 468.93% change year over year.
Biodesix Inc Equity Multiplier for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.94, a 614.85% change year over year.
Biodesix Inc Equity Multiplier for the Trailing 12 Months (TTM) ending March 31, 2020 was -0.18.

NASDAQ: BDSX

Biodesix Inc

CEO	Mr. Scott Hutton
IPO Date	Oct. 28, 2020
Location	United States
Headquarters	2970 Wilderness Place, Boulder, CO, United States, 80301
Employees	217
Sector	Healthcare
Industry	Diagnostics & research

Description

Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.

Key trends